Literature DB >> 19946341

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin.

P Tsirigotis1, M Y Shapira, R Or, M Bitan, S Samuel, B Gesundheit, A Ackerstein, A Abdul-Hai, S Slavin, I B Resnick.   

Abstract

The influence of graft composition on the outcome of reduced-intensity (RIC) allogeneic PBSC transplantation (allo-PBSC) remains controversial. In this study, we analyzed the impact of CD34+ cell dose on the incidence of GVHD, and on the outcome after allo-PBSC, in 103 patients with hematological malignancies, using a uniform RIC regimen. The following variables were included in statistical analysis: (1) number of C34+ cells, (2) high-risk vs low-risk disease status, (3) matched related vs matched unrelated donor, (4) female donor to male recipient vs any other combination, (5) age of recipient (above vs below the median). Univariate and multivariate analysis did not reveal any association between CD34+ cell dose and acute grade-2 to grade-4, cGVHD, non-relapse mortality (NRM), relapse rate (RR) and OS. High-risk disease status was the only variable independently associated with increased NRM (P=0.001), increased RR (P=0.012) and decreased OS (P<0.001). The same results were obtained when analysis was restricted to a subgroup of 55 patients with myeloid neoplasms. The influence of graft composition on the outcome of RIC allo-PBSC should be further investigated via well-controlled randomized prospective studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19946341     DOI: 10.1038/bmt.2009.331

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.

Authors:  P D Tsirigotis; I B Resnick; B Avni; S Grisariu; P Stepensky; R Or; M Y Shapira
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

2.  Impact of CD34+ cell dose in children who receive unrelated PBSCT with in vivo T-cell depletion for hematologic malignancies.

Authors:  J W Lee; S-K Kim; P-S Jang; N-G Chung; D-C Jeong; B Cho; H-K Kim
Journal:  Bone Marrow Transplant       Date:  2014-09-29       Impact factor: 5.483

3.  Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.

Authors:  Paul S Martin; Shuli Li; Sarah Nikiforow; Edwin P Alyea; Joseph H Antin; Philippe Armand; Corey S Cutler; Vincent T Ho; Natasha Kekre; John Koreth; C John Luckey; Jerome Ritz; Robert J Soiffer
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

4.  Impact of conditioning regimen on peripheral blood hematopoietic cell transplant.

Authors:  Michael Burns; Anurag K Singh; Carrie C Hoefer; Yali Zhang; Paul K Wallace; George L Chen; Alexis Platek; Timothy B Winslow; Austin J Iovoli; Christopher Choi; Maureen Ross; Philip L McCarthy; Theresa Hahn
Journal:  World J Clin Oncol       Date:  2019-02-24

Review 5.  The role of microglia in human disease: therapeutic tool or target?

Authors:  Nathalie Cartier; Coral-Ann Lewis; Regan Zhang; Fabio M V Rossi
Journal:  Acta Neuropathol       Date:  2014-08-09       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.